Genetic Susceptibility and Influence of the Microbiomae in Bullous Pemphigoid (MICROPB)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02874079|
Recruitment Status : Recruiting
First Posted : August 22, 2016
Last Update Posted : October 5, 2016
Autoimmune bullous dermatoses include pemphigus, bullous pemphigoid, pemphigoid gestationis, linear IgA dermatosis, mucous membrane pemphigoid, lichen planus pemphigoid, anti-p200 pemphigoid, epidermolysis bullosa acquisita and dermatitis herpetiformis. Autoimmune bullous dermatoses are rare and have an incidence of 20-60 new cases per 1 million person- year in Europe. The incidence of the individual entities is slight significantly different within Europe, but strongly also in comparison to other countries such as Kuwait, Singapore, USA and South America. The most common of these disorders is the bullous pemphigoid.
A considerable progress has been made in the last years to elucidate the pathogenic role of autoantibodies in these diseases. To this end, various in vitro and animal experiments have been used to understand some basic pathophysiological mechanisms in these diseases. Further studies are currently being carried out to explain a precise elucidation of the disease process and to be able to treat the patients targeted later.
At present, however, no data are available to explain why certain individuals develop the autoimmune disease and others do not. Epidemiological studies showed some triggers to the development of autoimmune dysregulation, e.g. drugs.
Furthermore, it has been shown that genetic factors play a role in the pathogenesis of the disease. A clear association with certain HLA regions have been shown in patients with pemphigus, e.g. about 95% of pemphigus patients from the group of Ashkenazi Jews have the HLA-DRB1*0402 haplotype. Recently, the first non-HLA gene associated with pemphigus was described. For other conditions such as bullous pemphigoid, pemphigoid gestationis or linear IgA dermatosis the association with HLA antigens is less pronounced. Another indication of the importance of the genetic background in these diseases can be elucidated from the observation of autoantibodies at a low concentration in healthy relatives of pemphigus patients.
|Condition or disease||Intervention/treatment||Phase|
|Bullous Pemphigoid||Other: Blood sample and cotton skin swabs||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Genetic Susceptibility and Influence of the Microbiomae in Bullous Pemphigoid|
|Study Start Date :||December 2015|
|Estimated Primary Completion Date :||October 2017|
|Estimated Study Completion Date :||March 2018|
Experimental: bullous pemphigoid
patients with bullous pemphigoid
Other: Blood sample and cotton skin swabs
Active Comparator: no bullous pemphigoid
patients with basal cell carcinoma or squamous cell carcinoma and without inflammatory skin disease
Other: Blood sample and cotton skin swabs
- HLA haplotype [ Time Frame: Day 1 ]the genetic susceptibility in patients bullous pemphigoid were studied by the search of an association between bullous pemphigoid and a particular HLA haplotype
- micro satellite markers [ Time Frame: Day 1 ]the genetic susceptibility in patients bullous pemphigoid were studied by the search of an association between bullous pemphigoid and micro satellite markers, or SNPs (single nucleotide polymorphisms)
- SNPs (single nucleotide polymorphisms) [ Time Frame: Day 1 ]the genetic susceptibility in patients bullous pemphigoid were studied by the search of an association between bullous pemphigoid and SNPs (single nucleotide polymorphisms)
- Skin's Bacteria [ Time Frame: Day 1 ]Analysis of skin microbiome (type and number of bacteria) of patients with bullous pemphigoid, compared with patients without bullous pemphigoid
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02874079
|Contact: Philippe BERNARDemail@example.com|
|Chu de Reims||Recruiting|
|Reims, France, 51092|
|Contact: Philippe BERNARD firstname.lastname@example.org|